Detail akcie Celcuity Rg online

Business Summary: Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Celcuity Inc revenues was not reported. Net loss increased 43% to $52.8M. Higher net loss reflects General & Administrative - Balancing v increase from $3M to $14.2M (expense), Interest Expense increase of 91% to $6.1M (expense), Stock-Based Compensation increase from $939K to $3.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.86 to -$0.97.